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Keypoints: 
Several vaccine candidates have been developed based on novel and traditional vaccine development 
models. 
COVID vaccine trials have generally excluded care home residents and frail older people, despite them 
being ear-marked as the earliest recipients in any national vaccination programme. 
Most trials show mild to moderate severity adverse events are common and self-limiting but less 
prevalent in older people. Serious adverse events are very rare. 
Phase II trials for many vaccines show good antibody responses. 





Several vaccines against COVID-19 are on the cusp of regulatory approval. Their safety and efficacy 
in older people is critical to their success. Though care home residents and older people are likely to 
be amongst the first to be vaccinated, these patient groups are usually excluded from clinical trials. 
Data from several Phase II trials have given cause for optimism, with strong antibody responses and 
reassuring safety profiles but, with the exception of AstraZeneca’s vaccine, recruited few older 
people. Overall, the sparse data from Phase II trials suggest a reduction in both antibody responses 
and mild to moderate adverse events in well older people compared to younger participants. Many 
of the Phase III trials have made a conscious effort to recruit more older people, and interim 
analyses of the Pfizer and Moderna vaccine have led to press releases announcing high degrees of 
efficacy. However, older people with co-morbidities and frailty have once again been largely 
excluded and there are no published data on safety and efficacy in this group. Although the speed 
and impact of the pandemic on older people with frailty justify an approach where they are offered 
vaccination first, patients and their carers and supervising health care professionals alike will need to 
make a decision on accepting vaccination based on limited evidence. Here we review the main 
candidate vaccines that may become available, with a focus on the evidence of safety and efficacy in 
older people.     
  
As the world prepares for a mass roll-out of newly approved COVID-19 vaccines, older people with 
frailty are taking centre stage. Recognising that this group had borne the brunt of the pandemic, 
with most excess deaths occurring in the oldest age groups [1], the UK government’s Vaccine Task 
Force strategy focussed on vaccines expected to elicit a good immune response in older people, 
stating it was ‘essential’ that they worked in this age group [2]. Residents in care homes and older 
people with co-morbidities are likely to be among the first to be vaccinated. But what is the evidence 
that the vaccines are safe and effective in this population? Here we briefly review the main 
candidate vaccines, with a focus on the evidence of their safety and efficacy and its relevance to the 
older population.        
A summary of the main COVID-19 vaccines being developed for potential use is shown in Table 1. 




Two of the vaccines reporting the earliest Phase III results, manufactured by Pfizer and Moderna, are 
novel mRNA vaccines. Both reported initial results suggesting efficacies in excess of 90%. They work 
by injecting mRNA encoding the SARS-CoV-2 spike protein directly into the host. Although pure 
mRNA is rapidly downgraded, a number of technological advances in delivery methods and RNA 
carriers over the last decade allow efficient and safe uptake of mRNA into the cytosol, where 
ribosomes then translate the mRNA to produce a viable protein that can then stimulate an immune 
response. This technology has a number of theoretical advantages over more conventional vaccine 
types, including improved safety (as no infectious agents are involved in their production), low 
potential for mutations, lower risk of antigen degradation in vivo, and the potential for rapid mass 
production at lower cost, as in vitro reactions can rapidly generate high yields of the therapeutic 
agent [3]. However, little is known about the efficacy and safety of mRNA vaccines in older people, 
especially at the extremes of old age and in those with frailty. A phase I study of the Moderna 
vaccine in ‘older adults’ published in the New England Journal of Medicine received considerable 
media attention after it found antibody responses were similar to those seen in younger people [4]. 
However, this study included only 40 healthy people aged 58 or over, so its relevance to older 
people with frailty is unclear. Self-limiting mild to moderate adverse events were common, with all 
20 participants aged 71 or over (mean age 72.6y) reporting local side effects such as pain at the 
injection site and 80% reporting systemic symptoms such as lethargy. Over 25% (around 8000) 
participants of the Moderna phase III study are aged 65 or over and a similar proportion have 
chronic diseases, so the evidence base will improve once full interim results are published. For the 
Pfizer vaccine, published data on older participants are even more sparse. However, a press release 
from Pfizer claimed over 95% efficacy in their over 65 age group (but with no supporting details or 
figures) [5] and over 40% of participants in their Phase III trial are aged between 56 and 84.  
 
Genetically modified organism (virus vector) vaccines 
The vaccines developed by both the University of Oxford/AstraZeneca (ChAdOx1) and Janssen 
(Ad26.COV2); frequently referred to as the Johnson & Johnson vaccine, particularly in the US media) 
rely on the genetic modification of adenoviruses that are inactivated due to deletion of the E1 gene 
which is replaced with the spike gene. The Janssen Ad26.COV2 vaccine is based on a human 
adenovirus while the Oxford vaccine is based on a chimpanzee (ChAdOx1) adenovirus, both of which 
are replication defective. The choice of a chimpanzee adenovirus in the Oxford design was to reduce 
the impact of human adenovirus antibodies acquired through natural exposure to human 
adenoviruses over time – a factor likely to be more important in elderly patients. Spike protein is 
expressed on the virus particle surface, triggering both antibody and T cell responses that may be 
protective against COVID-19. Use of genetically modified organisms as vaccines dates back to the 
early 1980s [6] and has the advantage that the safety of the adenovirus vector at low doses is well 
established and likely to be transferable to new vaccines, though the vector has never been used in 
large numbers of older people with frailty. Janssen’s phase II trial included just 15 participants aged 
65 and over, with rates of adverse events lower (36%) than in younger people (64%) [7]. More 
robust Phase II safety data have been published for the AstraZeneca vaccine, including 200 people 
aged 70 or over without severe comorbidities or frailty [8]. The vaccine was safe and well tolerated, 
with neutralising antibodies developing in almost 100% of participants at 28 days follow-up across all 
age groups. There were no serious or unexpected adverse events and, consistent with the findings 
for the Janssen study, the incidence of mild and moderate severity adverse events in the immediate 
post-vaccination period was lower in the older age groups. Both the AstraZeneca and Janssen 
vaccines are currently undergoing Phase III testing in the UK as part of international trials. Early 
results from the AstraZeneca vaccine suggested the vaccine averaged 70% efficacy overall. Of note, 
adenovirus vectored vaccines have also been developed and tested in China (Cansino Biological) and 
Russia (Gamileya Research Institute). Cansino’s vaccine elicited neutralising antibody and T-cell 
mediated responses in a dose-dependent manner with lower levels in those aged over 55. Gamileya 
reported in a press release its Sputnik vaccine was 92% effective, but this analysis was based on only 
20 positive cases and no age breakdown for the trial has been provided to date.                
 
Adjuvanted protein vaccines 
A more traditional approach to vaccine development is the use of purified protein extracts from the 
offending organism, usually given in combination with an adjuvant to boost the immune response. 
Both the Novavax and GSK/Sanofi vaccines consist of purified pre-fusion stabilised SARS-CoV-2 spike 
protein, harvested from genetically modified viruses, akin to those described above. Novavax has 
staged its first phase III study of 15000 people exclusively in the UK, with another planned in the USA 
due to start before the end of the year. Although the trials will recruit a minimum of 25% of people 
aged 65 and over, those aged 85 or over and those with complex comorbidity are excluded. Phase II 
data for older people have not been published to date – in younger people, much like the other 
candidate vaccines, a strong antibody response was observed with self-limiting mild to moderate 
local and systemic side effects observed in over a third of recipients [9]. The GSK/Sanofi candidate 
vaccine entered phase I/II trials in September, recruiting 400 healthy participants from the USA and 
is yet to report any results despite plans to start Phase III testing in December 2020. Therefore, 
published safety and efficacy data for adjuvanted protein vaccines in older people are currently 
minimal, though initial results from ongoing studies are expected imminently.     
 
Live-attenuated and inactivated virus vaccines 
Traditional vaccines have often involved live-attenuated or inactivated organisms. The principal 
advantage of such a vaccine is that the similarity to the natural infection may makes a stronger and 
longer-lasting immune response more likely. No one knows how long immunity lasts after infection 
with SARS-CoV-2, though the very few cases of confirmed re-infection since the start of the 
pandemic suggests a high level of immunity is conferred for a minimum of one year and possibly 
much longer. However, live vaccines may be risky in those with immunosuppression and frail 
immune systems, potentially including those at highest risk of COVID-19 such as older people with 
frailty. Consequently, there are few live-attenuated vaccines in development. A safer alternative 
may be  to develop inactivated viruses, though these generally confer less long-acting immunity and 
typically require regular boosters [6,10]. Valneva has developed an inactivated SARS CoV2 virus that 
is ready for testing in Phase I/II trials prior to commencing Phase III in early 2021. China has also 
developed two inactivated virus vaccines showing promising antibody responses and low adverse 
events, with both lower in older age groups but only up to the age of 59. No data are yet available 
from Phase III studies or their Phase I/II study in people aged over 60 .  
Generalisability to older people with frailty 
The efficacy of vaccines in general in older people is not well studied [11]. Typically, surrogate 
markers of efficacy measures are antibody titres, antibody isotypes and the ability of the immune 
system to neutralise pathogens. Immunosenescence is a broad term used to encompass declining 
immunity with age, encompassing both quantitative and qualitative aspects of immune system 
responses that are likely to impact on the observed safety and efficacy profile of vaccines. With 
advancing age there is a reduction in naive T cells available to respond to a vaccine. The normal ratio 
of CD4:CD8 cells becomes much higher in older age, due to a significant decrease in CD8 T cells. 
Ageing also brings a loss of T cell receptor diversity in both CD8 and CD4 cells, and overall reduced T 
cell survival. Qualitative changes include the favoured production of short-lived effector T cells over 
memory precursor cells, resulting in an impaired response of T follicular helper cells to vaccination. 
Naive T cells are also genetically and phenotypically more alike to central memory T cells than they 
are in a younger population, impacting their plasticity [11]. B cell numbers remain more consistent 
with age but, due to a reduced expression of select proteins in old age, fewer functional antibodies 
are produced [12]. Theoretically therefore, vaccines are likely to be somewhat less effective in older 
people. Moreover, the relative importance of cellular aspects of the immune response in COVD-19 is 
unclear, even more so in older people, so antibody levels may not be adequate surrogates for 
immunity [13]. The impact of immunosenescence on vaccine safety is even more uncertain. Though 
the risk of serious adverse events mediated by over-activation of the immune system is theoretically 
lower, this may be offset by increased predisposition to adverse events overall, as this is the 
hallmark of frailty. 
Perspective    
In summary, it is likely that a vaccine programme will be rolled out starting with older people with 
frailty despite scant evidence of efficacy or safety in this group. The rapidly evolving and devastating 
nature of the pandemic arguably justifies this approach and health officials will want to atone for 
mistakes made in the first wave, where a policy of discharging hospitalised care home residents with 
COVID-19 whilst still infectious led to outbreaks and cost lives [14]. The exclusion of older people, 
particularly those with frailty, from clinical trials of therapeutics that they may most benefit from has 
been recognised for decades [15].  Although the speed with which vaccines have been developed, 
tested and rolled out has been rightly widely lauded, it is a pity that some old habits have remained 
unchanged. The safety and efficacy of COVID-19 vaccines in the population that should most benefit 
from them may only become apparent after they have been given.  No pharmacovigilance studies 
have been formally proposed or announced. Key information on safety and efficacy may therefore 
need to be acquired retrospectively through usual regulatory authority surveillance systems and 
epidemiological studies, though no design can substitute for the information that could have been 
acquired in more inclusive randomised controlled trials. Even the benefits of annual vaccination of 
older people against influenza are unquantified and disputed [16], so the same may occur with 
COVID-19 vaccination programmes. Some may argue that the inclusion of older people with frailty or 
complex co-morbidity would slow down development of a working vaccine, as the risk of severe 
adverse events and pauses to trials increase. However, trials in these populations are possible and 
judicious application of pause rules and other safety criteria could mitigate against the risk of 
unnecessary and costly delays. Better engagement between teams working on vaccine trials and 
those with experience of running trials in older people with frailty is needed to help achieve a closer 
match between trial and key ‘real world’ populations.      
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Table 1: Experimental COVID-19 vaccines  
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